Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-745-1700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42 million
Profitability
Miscellaneous
Employees75
OptionableOptionable
Ardelyx (NASDAQ:ARDX) Frequently Asked Questions
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx Inc (NASDAQ:ARDX) posted its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.02. View Ardelyx's Earnings History.
When is Ardelyx's next earnings date?
What price target have analysts set for ARDX?
5 equities research analysts have issued 1-year target prices for Ardelyx's stock. Their predictions range from $7.00 to $13.00. On average, they anticipate Ardelyx's stock price to reach $10.75 in the next twelve months. This suggests a possible upside of 311.9% from the stock's current price. View Analyst Price Targets for Ardelyx.
What is the consensus analysts' recommendation for Ardelyx?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.
Has Ardelyx been receiving favorable news coverage?
News stories about ARDX stock have trended negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ardelyx earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include Vectura Group (VEGPF), Eagle Pharmaceuticals (EGRX), Basilea Pharmaceutica (BPMUF), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Assembly Biosciences (ASMB), AMAG Pharmaceuticals (AMAG), Lexicon Pharmaceuticals (LXRX), Kura Oncology (KURA), Karyopharm Therapeutics (KPTI), Aurinia Pharmaceuticals (AUPH), Akorn (AKRX), Urogen Pharma (URGN), Flexion Therapeutics (FLXN) and ChemoCentryx (CCXI).
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- Mr. Michael G. Raab, Pres, CEO & Director (Age 54)
- Mr. David Rosenbaum, Chief Devel. Officer (Age 58)
- Mr. Mark E. Kaufmann, CFO & Treasurer (Age 51)
- Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 65)
- Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 56)
Who are Ardelyx's major shareholders?
Ardelyx's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.32%), Pekin Singer Strauss Asset Management IL (4.25%), Dimensional Fund Advisors LP (2.65%), 683 Capital Management LLC (1.46%), Geode Capital Management LLC (1.09%) and D. E. Shaw & Co. Inc. (0.83%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Gordon Ringold, Jeremy S Caldwell, Mark Kaufmann, Michael Raab, Reginald Seeto and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.
Which major investors are selling Ardelyx stock?
ARDX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Algert Global LLC, Connor Clark & Lunn Investment Management Ltd., IHT Wealth Management LLC and UBS Oconnor LLC. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, Michael Raab and Scott D Sandell. View Insider Buying and Selling for Ardelyx.
Which major investors are buying Ardelyx stock?
ARDX stock was acquired by a variety of institutional investors in the last quarter, including Pekin Singer Strauss Asset Management IL, 683 Capital Management LLC, D. E. Shaw & Co. Inc., Wedbush Securities Inc., Squarepoint Ops LLC, Dimensional Fund Advisors LP, RBF Capital LLC and Geode Capital Management LLC. View Insider Buying and Selling for Ardelyx.
How do I buy shares of Ardelyx?
Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of ARDX stock can currently be purchased for approximately $2.61.
How big of a company is Ardelyx?
Ardelyx has a market capitalization of $162.17 million and generates $42 million in revenue each year. The biopharmaceutical company earns $-64,330,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Ardelyx employs 75 workers across the globe.
What is Ardelyx's official website?
How can I contact Ardelyx?
Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]
MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
